Using JAK2 MutaScreen assay (assay sensitivity of 2%) to detect JAK2V617F, the presence of JAK2V617F mutation in our PMF patients was found to be significantly higher as compared to ET patients (75.3% and 59.8%, respectively). Here, JAK2 is linked to essential thrombocythemia.